Orthogonal analytical approaches to detect potential contaminants in heparin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 40, 2009, Pages 16956-16961

  Guerrini, Marco ^a   Zhenqing, Zhang ^b   Shriver, Zachary ^c   Naggi, Annamaria ^a   Masuko, Sayaka ^b   Langer, Robert ^c   Casu, Benito ^a   Linhardt, Robert J ^b   Torri, Giangiacomo ^a   Sasisekharan, Ram ^c  

^a Istituto di Richerche Chimiche E Biochimiche G Ronzoni   (Italy)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Anticoagulant; Capillary electrophoresis; Contamination; NMR; Oversulfated chondroitin

Indexed keywords

CHONDROITIN SULFATE; HEPARIN; POLYSACCHARIDE;

ANTICOAGULATION; ARTICLE; CAPILLARY ELECTROPHORESIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ANIMALS; ANTICOAGULANTS; CATTLE; CHONDROITIN SULFATES; DRUG CONTAMINATION; ELECTROPHORESIS, CAPILLARY; HEPARIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY OF RESULTS; SWINE;

EID: 70350133604     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906861106     Document Type: Article

References (41)

1. Linhardt RJ (2003) 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: Structure and activity. J Med Chem 46:2551-2564.
2. Casu B, Lindahl U (2001) Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 57:159-206. (Pubitemid 34121000)
3. Linhardt RJ, Gunay NS (1999) Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25:5-16. (Pubitemid 29517028)
4. Liu H, Zhang Z, Linhardt RJ (2009) Lessons learned from the contamination of heparin. Nat Prod Rep 26:313-321.
5. Griffin CC, et al. (1995) Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. Carbohydr Res 276:183-197.
6. Conrad HE (1998) Heparin-Binding Proteins (Academic, San Diego).
7. Volpi N (1993) "Fast moving" and "slow moving" heparins, dermatan sulfate, and chondroitin sulfate: Qualitative and quantitative analysis by agarose-gel electrophoresis. Carbohydr Res 247:263-278.
8. Bianchini P, et al. (1985) Fractionation and structural features of two heparin families with high antithrombotic, antilipemic and anticoagulant activities. Arzneimittelforschung 35:1215-1219. (Pubitemid 16240616)
9. Casu B (1989) Methods is Structural Analysis in Heparin: Chemical and Biological Properties and Clinical Applications, eds Lane DA, Lindahl U (CRC Press, New York).
10. Anonymous (Proposed USP Monograph Revision.).
11. Zhang Z, et al. (2009) Analysis of pharmaceutical heparins and potential contaminants using 1H-NMR and PAGE. J Pharm Science, 10.1002/jsp.21729.
12. Kishimoto TK, et al. (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457-2467. (Pubitemid 351793019)
13. Guerrini M, et al. (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669-675. (Pubitemid 351824692)
14. Blossom DB, et al. (2008) Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 359:2674-2684.
15. Gallagher JT, Turnbull JE, Lyon M (1992) Patterns of sulphation in heparan sulphate: Polymorphism based on a common structural theme. Int J Biochem 24:553-560.
16. Liu J, Desai UR, Han XJ, Toida T, Linhardt RJ (1995) Strategy for the sequence analysis of heparin. Glycobiology 5:765-774.
17. Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G (2005) Complex glycosaminoglycans: Profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 337:35-47. (Pubitemid 40092776)
18. Toida T, et al. (1999) Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans. Int J Biol Macromol 26:233-241. (Pubitemid 29494940)
19. Maruyama T, Toida T, Imanari T, Yu G, Linhardt RJ (1998) Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 306:35-43. (Pubitemid 28304973)
20. Casu B, et al. (1994) Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res 263:271-284. (Pubitemid 24320402)
21. Yates EA, et al. (2000) Effect of substitution pattern on 1H, 13CNMRchemical shifts and 1J(CH) coupling constants in heparin derivatives. Carbohydr Res 329:239-247.
22. Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G (2007) Low molecular weight heparins: Structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 33:478-487.
23. Yamaguchi H, Shinagawa M, Shimba N, Miyano H, Suzuki E (2008) NMR analysis of a contaminant in heparin. Yakugaku Zasshi 128:1513-1515.
24. Bigler P, Brenneisen R (2009) Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy. J Pharm Biomed Anal 49:1060-1064.
25. Beyer T, et al. (2008) Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 48:13-19.
26. Hu P, Fang L, Chess EK (2009) Source-induced fragmentation of heparin, heparan, and galactosaminoglycans and application. Anal Chem 81:2332-2343.
27. Spencer JA, et al. (2009) Screening of heparin API by near infrared reflectance and Raman spectroscopy. J Pharm Science, 10.1002/jps.21660.
28. Norwig J, et al. (2009) Prediction of the oversulphated chondroitin sulphate contamination of unfractionated heparin by ATR-IR spectrophotometry. Pharmeur Sci Notes 2009:17-24.
29. Wielgos T, Havel K, Ivanova N, Weinberger R (2009) Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers. J Pharm Biomed Anal 49:319-326.
30. Volpi N, Maccari F, Linhardt RJ (2009) Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations. Anal Biochem 388:140-145.
31. Somsen GW, Tak YH, Torano JS, Jongen PM, de Jong GJ (2009) Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis. J Chromatogr A 1216:4107-4112.
32. Trehy ML, Reepmeyer JC, Kolinski RE, Westenberger BJ, Buhse LF (2009) Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal 49:670-673.
33. WangL, Buchanan S, MeyerhoffME(2008) Detection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors. Anal Chem 80:9845-9847.
34. Tami C, et al. (2008) Inhibition of Taq polymerase as amethod for screening heparin for oversulfated contaminants. Biomaterials 29:4808-4814.
35. Bairstow S, McKee J, Nordhaus M, Johnson R (2009) Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products. Anal Biochem 388:317-321.
36. Li B, et al. (2009) Oversulfated chondroitin sulfate interaction with heparin-binding proteins: New insights into adverse reactions from contaminated heparins. Biochem Pharmacol 78:292-300.
37. Naggi A, et al. (2001) Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost 27:437-443. (Pubitemid 32989368)
38. Rej RN, Ludwig-Baxter KG, Perlin AS (1991) Sulfation of some chemically-modified heparins. Formation of a 3-sulfate analog of heparin. Carbohydr Res 210:299-310.
39. Yates EA, et al. (1996) 1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res 294:15-27. (Pubitemid 26388787)
40. Toida T, et al. (1997) Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species. Biochem J 322:499-506. (Pubitemid 27116576)
41. Viskov C, et al. (2009) Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Clin Appl Thromb Hemost, in press.